Clinical Trials Browser

Adenocarcinoma, Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Adjuvant Drug Therapy

Breast Neoplasms

Neuroendocrine Tumors

Nasopharyngeal Carcinoma

Pancreatic Neoplasms

Advanced Rectal Cancer

Breast Neoplasm Malignant Female

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Breast Neoplasms

Gastrointestinal Neoplasms

Locally Advanced Gastric Cancer

Rectal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Glioblastoma, Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Childhood Solid Tumor

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Adenocarcinoma

Clinical Stage I Gastric Cancer AJCC v8

Esophageal Neoplasms

Pancreatic Ductal Adenocarcinoma

Breast Neoplasms, Neoplasm Metastasis

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Breast Neoplasms

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Breast Neoplasms

Biliary Tract Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

Biliary Tract Neoplasms

Colorectal Cancer Metastatic

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Stomach Neoplasms

Advanced Solid Tumour

Breast Neoplasms, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Rectal Neoplasms

Stomach Neoplasms

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

Clinical Trials

LUCERNA

ASPEN-09-03

STARTER

Capecitabine in ER+/HER2-negative Breast Cancer

CapTemY90

RAIRI-NPC

Pan Tumor Rollover Study

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer

DPDMAX

STAR-221

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer

K-BOOST

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

CAPTEM

DELUMA

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Metro-PD1

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

NeoB-Cap1

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

ORCHID

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

MK-3475-06C

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

OPTICAL

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

MK-2870-010

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

TriComB

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

EVOLVE-BDT

HERIZON-GEA-01

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

GRECCAR12

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)